Data reported through a smartphone app provides the first detailed description of COVID-19 in symptomatic school-aged children.

Data reported through a smartphone app provides the first detailed description of COVID-19 in symptomatic school-aged children.
Citing concern over vaccine efficacy against emerging variants, Pfizer seeks approval for a third booster, but many are not yet convinced it is necessary.
Small clinical trial has found that metabolic activators can improve recovery, liver health, and markers of inflammation in patients with COVID-19.
The protein-based vaccine has been highly anticipated, showing high efficacy against variants of concern.
Study shows that temperature changes have a smaller effect on transmission than policy interventions like lockdowns and social distancing.
Viruses are so varied and evolve so quickly that creating effective treatments against them becomes a daunting task.
Emerging data from trials exploring mixing different types of vaccines demonstrate the practice is safe and could boost immunity.
In a historic and surprise move, this week the US declared its support for a patent waiver on COVID-19 vaccines.
Assays using pseudoviruses have been indispensable in our efforts to halt the current pandemic.
The strength of immune responses after the first dose of COVID-19 vaccines could make or break this strategy and policy makers need to be able to adapt.